Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over

  • Highly specialised technologies guidance
  • HST33
  • Published: 
Download guidance (PDF)

2 Information about leniolisib

Marketing authorisation indication

2.1

Leniolisib (Joenja, Pharming) is indicated for 'the treatment of activated phosphoinositide 3‑kinase delta (PI3Kδ) syndrome (APDS) in adult and paediatric patients 12 years of age and older'.

Dosage in the marketing authorisation

Price

2.3

The list price of leniolisib is £36,670 per pack of 60 tablets (excluding VAT; NHS Business Services Authority [NHSBSA] dictionary of medicines and devices [dm+d] browser; accessed October 2025).

2.4

The company has a commercial arrangement. This makes leniolisib available to the NHS with a discount. The size of the discount is commercial in confidence.